Multiple sclerosis journal - experimental, translational and clinical · 2025
Delphi panel to understand the real-world occurrence and management of ofatumumab injection-related reactions among healthcare providers of people with relapsing multiple sclerosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saidha Shiv, Kramer John, Brown Brandon, Brewer Iris, Chou Jacquelyn W, Graf Marlon, Wilson Rozanne, Greenberg Benjamin M
Аннотация
BACKGROUND: People with relapsing forms of multiple sclerosis (PwRMS) treated with ofatumumab, a fully human anti-CD20 monoclonal antibody, can experience local/systemic injection-related reactions (IRRs). However, data on the occurrence and management of local/systemic IRRs in real-world clinical settings are limited.
OBJECTIVE: This study aimed to better understand clinicians' perspectives regarding occurrence and management of local/systemic IRRs among PwRMS treated with ofatumumab in clinical practice.
METHODS: A panel of US-based neurologists and advanced practice providers experienced with ofatumumab therapy in PwRMS participated in a three-round online modified Delphi study. In round 1, participants completed a demographics survey and Delphi questionnaire on IRR management. In round 2, they attended a live webinar to obtain feedback on round 1 results. In round 3, they reviewed round 1 and 2 feedback and provided their final responses.
RESULTS: Forty participants (neurologists, n = 31; nurse practitioners, n = 5; and physician assistants, n = 4) completed all three rounds. Participants strongly agreed that local/systemic IRRs, regardless of severity, were unlikely with ofatumumab. Pre-/post-treatment of systemic IRRs was not uniformly required.
CONCLUSION: This study gives health care providers insight into the potential occurrence and management of IRRs with ofatumumab in the clinical practice setting.
OBJECTIVE: This study aimed to better understand clinicians' perspectives regarding occurrence and management of local/systemic IRRs among PwRMS treated with ofatumumab in clinical practice.
METHODS: A panel of US-based neurologists and advanced practice providers experienced with ofatumumab therapy in PwRMS participated in a three-round online modified Delphi study. In round 1, participants completed a demographics survey and Delphi questionnaire on IRR management. In round 2, they attended a live webinar to obtain feedback on round 1 results. In round 3, they reviewed round 1 and 2 feedback and provided their final responses.
RESULTS: Forty participants (neurologists, n = 31; nurse practitioners, n = 5; and physician assistants, n = 4) completed all three rounds. Participants strongly agreed that local/systemic IRRs, regardless of severity, were unlikely with ofatumumab. Pre-/post-treatment of systemic IRRs was not uniformly required.
CONCLUSION: This study gives health care providers insight into the potential occurrence and management of IRRs with ofatumumab in the clinical practice setting.